Latest News
Featured News
Scancell to present positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Notice of Results
Director Dealing
Director Dealing
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
Share Option Exercise
Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
No results found.
Regulatory News Archive
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.